Beta-blockers use and 1-year mortality in HFmrEF: mortality was reduced in HFmrEF with CAD [HR up to 1 year 0.74, 95% CI (0.59, 0.92)] but not in HFmrEF without CAD [HR 0.99, 95% CI (0.78, 1.26)]; angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARBs)/statins were associated with reduced risk in all HFmrEF groups with or without CAD (all p ≤ 0.004). This evidence concerns the gene ACE and coronary artery disorder.